MAIA Biotechnology, Inc.
MAIA$49M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCHICAGO13 employees
MAIA Biotechnology, Inc. is a public, immune-oncology company based in Chicago, IL focused on the development of telomere targeting agents for the treatment of telomerase-positive cancer cells.
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
This month
Market Overview
Stock performance and key metrics
MAIA News
Catalyst Timeline
2 upcoming, 0 past
Phase 2Next
6-Thio-2'-Deoxyguanosine Phase 2 Est. Readout
June 2026~Confirmed6-Thio-2'-Deoxyguanosine227
Primary completion for 6-Thio-2'-Deoxyguanosine trial (NCT05208944) in Carcinoma, Non-Small-Cell Lung
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Drug Pipeline
Cemiplimab
Carcinoma, Non-Small -Cell Lung
6-Thio-2'-Deoxyguanosine
Carcinoma, Non-Small-Cell Lung
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cemiplimab | Phase 3 | Carcinoma, Non-Small -Cell Lung | - | - |
6-Thio-2'-Deoxyguanosine | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply